Sandal India Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.20 M
as on 20-06-2024
- Paid Up Capital ₹ 1.20 M
as on 20-06-2024
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -13.40%
(FY 2021)
- Profit -16.68%
(FY 2021)
- Ebitda -23.46%
(FY 2021)
- Net Worth 5.82%
(FY 2021)
- Total Assets -3.43%
(FY 2021)
About Sandal India Pharmaceuticals
The Corporate was formerly known as Sandal India Pharmaceuticals Marketing Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 M and a paid-up capital of Rs 1.20 M, as per Ministry of Corporate Affairs (MCA) records.
Sushma Kumari, Amrendra Kumar, Anil Singh, and Three other members serve as directors at the Company.
- CIN/LLPIN
U00064BR2004PTC010980
- Company No.
010980
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Oct 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Muzaffarpur, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sandal India Pharmaceuticals?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushma Kumari  | Director | 19-Apr-2007 | Current |
| Amrendra Kumar | Director | 30-Nov-2005 | Current |
| Anil Singh | Director | 05-Oct-2004 | Current |
| Lakhan Prasad | Director | 05-Oct-2004 | Current |
| Vinay Kumar | Director | 05-Oct-2004 | Current |
| Navin Kumar | Director | 05-Oct-2004 | Current |
Financial Performance of Sandal India Pharmaceuticals.
Sandal India Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 13.4% decrease. The company also saw a substantial fall in profitability, with a 16.68% decrease in profit. The company's net worth moved up by a moderate rise of 5.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sandal India Pharmaceuticals?
In 2021, Sandal India Pharmaceuticals had a promoter holding of 89.00% and a public holding of 11.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sandal India Pharmaceuticals?
Unlock and access historical data on people associated with Sandal India Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sandal India Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sandal India Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
